Adalimumab for Psoriatic and Early Rheumatoid Arthritis in Europe

Adalimumab

The European Commission has approved adalimumab (Humira®, Abbott) to treat psoriatic arthritis and early rheumatoid arthritis (RA) in Europe. A decision regarding the FDA’s approval for these expanded indications in the U.S. is expected by the end of 2005.

The medication will be available immediately to patients with psoriatic arthritis in Germany, the United Kingdom, Spain, Finland, and Denmark and later in other European Union countries as each country adopts pricing and reimbursement policies.
canadian pharmacy online

The recommended dose for psoriatic arthritis, as well as the usual dose for RA, is 40 mg every other week by subcutaneous injection.

The drug was previously approved for moderate-to-severe, active RA in adults who did not adequately respond to disease-modifying antirheumatic drugs, including methotrexate.